Document is current
Any future updates will be listed below
-
Authors
Park, Jong Ho
Mortaja, Mahsa
Son, Heehwa G.
Zhao, Xutu https://orcid.org/0009-0003-0856-3481
Sloat, Lauren M. https://orcid.org/0000-0003-1315-1302
Azin, Marjan
Wang, Jun
Collier, Michael R.
Tummala, Krishna S.
Mandinova, Anna
Bardeesy, Nabeel https://orcid.org/0000-0003-3867-0416
Semenov, Yevgeniy R.
Mino-Kenudson, Mari https://orcid.org/0000-0002-9092-2265
Demehri, Shadmehr https://orcid.org/0000-0002-7913-2641
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR068619, R01AR076013)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
Burroughs Wellcome Fund (CAMS)
Sidney Kimmel Foundation (Scholar)
- License Information
-
More Information
Article History
Received: 20 April 2023
Accepted: 24 April 2024
First Online: 30 May 2024
Competing interests
: J.H.P. and S.D. are coinventors on a filed patent for the use of IL-33 inhibition in treating cancer, fibrosis, and inflammation (PCT/US21/40725). A.M. is an equity holder of DermBiont Inc. The remaining authors state no conflict of interest.
